ERC Einstein Rockefeller CUNY Center for AIDS Research

ERC 爱因斯坦洛克菲勒纽约市立大学艾滋病研究中心

基本信息

批准号：
10605270
负责人：
Joan Weinberger Berman
金额：
$ 35.96万
依托单位：
ALBERT EINSTEIN COLLEGE OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-05-01 至 2027-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10605270
关键词：
Acceleration Acquired Immunodeficiency Syndrome Animal Model Anti-Retroviral Agents Antigens Antiviral Agents Articulation Biochemical Bioinformatics Biological Assay Biological Markers Biological Products Biology Blood Body Fluids Brain Cell Culture Techniques Cell Separation Cells Cellular Immunity Characteristics Clinical Clinical Sciences Collaborations Consultations DNA Development Drug Kinetics Effectiveness Enzyme-Linked Immunosorbent Assay Epidemic Freezing Future Goals HIV HIV Infections HIV risk HIV/AIDS Human Humoral Immunities Immune Immunotherapy In Vitro Infrastructure Insecta Institution Knowledge Leadership Life Cycle Stages Ligands Link Liquid substance Macrophage Mass Spectrum Analysis Measurement Mental Health Mentors Mentorship Modeling Participant Pathogenesis Patients Peripheral Blood Mononuclear Cell Persons Pharmaceutical Preparations Pharmacodynamics Prevention approach Process Production Prophylactic treatment Proteins Proteomics RNA Reagent Research Research Personnel Resources Risk Sampling Science Services Technology Therapeutic Training Translational Research Vaccines Viral Virus antibody-dependent cell cytotoxicity antiretroviral therapy biomarker performance cell type comorbidity experience forging implementation research improved in vivo innovative technologies medication compliance member metabolomics microbiome analysis monocyte new technology next generation novel novel strategies pre-exposure prophylaxis prevent programs receptor recruit response small molecule synergism therapy adherence tissue culture transcriptomics treatment as prevention working group

项目摘要

PROJECT SUMMARY ERC-CFAR: BIOMARKER AND ADVANCED TECHNOLOGY CORE (BATC) To support the overarching goal of the ERC-CFAR to end the HIV epidemic, the Biomarker and Advanced Technology Core (BATC) provides state-of-the-art technologies, services and consultations to enhance our understanding of HIV biology and mechanisms and accelerate the development of novel approaches for prevention and cure. The BATC supports implementation research to improve the effectiveness of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP) and treatment as prevention (TasP). The BATC infrastructure supports established and early stage HIV/AIDS researchers as well as new investigators who are expanding their research to include HIV/AIDS-related studies at Einstein, Rockefeller, and CUNY. The leadership provides unique consultation services that leverage their experience to identify opportunities within and outside the BATC. The BATC provides cutting-edge services for our investigators and members of the HIV and Mental Health Scientific Working Group to accomplish their research, mentors and trains the next generation of HIV investigators, recruits established investigators into HIV research, and forges new collaborations across Einstein, Rockefeller and CUNY and other regional academic centers. The Aims of the BATC are: 1) Provide investigators with technological support to examine and evaluate novel approaches to prevent, treat and cure HIV infection and to characterize HIV pathogenesis. The BATC provides a wide array of services including biomarker assays and measurement of antiretroviral drug adherence, which are critical for PrEP, PEP and TasP studies. The BATC analyzes body fluids, culture supernatants and cell lysates for immune molecules and antiviral drug pharmacokinetics/pharmacodynamics using high-throughput multiplex platforms, ELISAs, and mass spectrometry. The BATC provides isolated cell types from human leukopaks and from blood from people with HIV (PWH). The BATC serves as a liaison with the Clinical and Translational Science Core to process blood from PWH leukapharesed at Einstein or Rockefeller to isolate and freeze various cell types for future use by ERC-CFAR investigators. The BATC will customize assays for HIV RNA/DNA quantification and import and establish cutting edge technologies; 2) Provide investigators with state-of-the-art technologies in the Protein Sciences to support studies of HIV biology, mechanism, and treatment. The BATC provides critical protein reagents for development of novel biologics for HIV eradication, protein antigens to study cellular and humoral immunity, and large quantities of materials for structural and biochemical characterization of proteins and assemblies critical for HIV infection and life cycle. It provides unique cell-based assays to characterize receptor-ligand interactions, including those linked to antibody dependent cell mediated cytotoxicity, a critical aspect of vaccines and immunotherapies; 3) Implement and evaluate the utility and feasibility of new technologies for inclusion within BATC. The BATC implemented bioinformatics services and is evaluating new technologies for inclusion within the BATC, including metabolomics and proteomics.

项目概要 ERC-CFAR：生物标志物和先进技术核心 (BATC) 为了支持 ERC-CFAR 结束艾滋病毒流行的总体目标，生物标记物和高级技术核心 (BATC) 提供最先进的技术、服务和咨询，以增强我们的能力了解艾滋病毒生物学和机制并加速开发新方法防治。 BATC 支持实施研究以提高预曝光的有效性预防 (PrEP)、暴露后预防 (PEP) 和治疗即预防 (TasP)。 BATC 基础设施支持已建立的早期艾滋病毒/艾滋病研究人员以及新的研究人员扩大他们的研究范围，包括在爱因斯坦、洛克菲勒和纽约市立大学进行与艾滋病毒/艾滋病相关的研究。领导层提供独特的咨询服务，利用他们的经验来识别内部和外部的机会 BATC。 BATC 为我们的研究人员以及艾滋病毒和精神科的成员提供尖端服务健康科学工作组完成他们的研究，指导和培训下一代艾滋病毒调查员，招募已建立的艾滋病毒研究调查员，并在爱因斯坦之间建立新的合作，洛克菲勒和纽约市立大学等地区学术中心。 BATC 的目标是： 1) 提供研究人员在技术支持下检查和评估预防、治疗和评估新方法治愈 HIV 感染并描述 HIV 发病机制。 BATC 提供广泛的服务包括生物标志物测定和抗逆转录病毒药物依从性测量，这对于 PrEP、PEP 至关重要和 TasP 研究。 BATC 分析体液、培养上清液和细胞裂解物中的免疫分子使用高通量多重平台、ELISA 和抗病毒药物药代动力学/药效学质谱分析。 BATC 提供从人类白细胞和人类血液中分离的细胞类型感染艾滋病毒（艾滋病毒感染者）。 BATC 充当与临床和转化科学核心处理血液的联络人来自爱因斯坦或洛克菲勒的 PWH 白细胞分离和冷冻各种细胞类型以供将来使用 ERC-CFAR 调查员。 BATC 将定制 HIV RNA/DNA 定量分析并导入和建立尖端技术； 2）为研究人员提供最先进的技术蛋白质科学支持 HIV 生物学、机制和治疗的研究。 BATC 提供了关键的用于开发消灭艾滋病毒的新型生物制剂的蛋白质试剂，用于研究细胞和蛋白质抗原体液免疫，以及用于蛋白质结构和生化表征的大量材料以及对 HIV 感染和生命周期至关重要的组件。它提供了独特的基于细胞的测定来表征受体-配体相互作用，包括与抗体依赖性细胞介导的细胞毒性相关的相互作用，这是一个关键的疫苗和免疫疗法方面； 3）实施并评估新的实用性和可行性纳入 BATC 的技术。 BATC 实施了生物信息学服务，并正在评估纳入 BATC 的新技术，包括代谢组学和蛋白质组学。